Meeting
2013 ASCO Annual Meeting
A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC).
Authors
Puneeth Iyengar
UT Southwestern Medical Center, Dallas, TX
Puneeth Iyengar , Brian D. Kavanagh , Irma Smith , Chul Ahn , David E. Gerber , Johnathan Dowell , Randall S. Hughes , Ramzi Abdulrahman , D. Ross Camidge , Laurie E. Gaspar , Robert Charles Doebele , Paul A. Bunn Jr., Hak Choy , Robert D. Timmerman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00547105
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8074)
DOI
10.1200/jco.2013.31.15_suppl.8074
Abstract #
8074
Poster Bd #
36F
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial.
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.
First Author: Fatemeh Ardeshir-Larijani
Poster
2015 ASCO Annual Meeting
Single institution experience with 75 mg dose of erlotinib in Latin American patients with mutated metastatic non-small cell lung cancer.
First Author: Osvaldo Rudy Aren
Poster
2014 ASCO Annual Meeting
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
First Author: Joel W. Neal